Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ERBB4 G741R |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ERBB4 G741R | Advanced Solid Tumor | sensitive | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) inhibited growth of a transformed cell line expressing ERBB4 G741R in culture (PMID: 36860695). | 36860695 | |
ERBB4 G741R | Advanced Solid Tumor | sensitive | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nerlynx (neratinib) inhibited growth of a transformed cell line expressing ERBB4 G741R in culture (PMID: 36860695). | 36860695 | |
ERBB4 G741R | Advanced Solid Tumor | sensitive | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vizimpro (dacomitinib) inhibited growth of a transformed cell line expressing ERBB4 G741R in culture (PMID: 36860695). | 36860695 | |
ERBB4 G741R | Advanced Solid Tumor | resistant | Erlotinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB4 G741R were resistant to Tarceva (erlotinib) treatment in culture (PMID: 36860695). | 36860695 |